[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad Peruana Cayetano Heredia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":117},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,66,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100544321","phase-2-one-and-two-doses-of-oxfendazole-versus-a-schedule-of-two-doses-of-triclabendazole-in-chronic-fascioliasis-100544321",false,"NCT06367361","One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis","A Non-Inferiority, Randomized, Blind Laboratory Analysis, Controlled Trial Comparing One and Two Doses Regimes of Oxfendazole Versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis","Inclusion Criteria:\n\n1. Male and female subjects eighteen years or older with positive stool microscopy and\u002For egg counts confirmed by qualitative and\u002For quantitative stool microscopy performed within the past 14 days.\n2. Subjects capable of understanding the informed consent process and providing written informed consent.\n3. Willingness to give informed consent.\n\nExclusion Criteria:\n\n1. Subjects reporting previous treatment for fascioliasis\n2. Subjects with a stool egg count \\> 300 eggs\u002Fg in stool samples\n3. Women with a positive urine pregnancy test or planning to become pregnant\n4. Women that are nursing\n5. Alanine aminotransferase (ALT) ≥ 3 or Aspartate aminotransferase (AST) ≥ 3 times above the upper limit of normal within 14 days before enrollment.\n6. Subjects with active cerebral cysticercosis determined by serology and imaging studies\n7. Subjects with known liver disease, liver cirrhosis, or end stage renal disease\n8. Subjects with known allergy or AEs to benzimidazole drugs\n9. Subjects taking carbamazepine, phenobarbital, phenytoin, or other medication known to decrease the serum concentrations of benzimidazoles.\n10. Women unable or unwilling to use an acceptable birth control method.\n11. Male volunteers who are unwilling to ensure pregnancy prevention in their partner.\n12. Volunteers with a previously recorded electrocardiogram showing heart-rate corrected (QTc) prolongation, or who are taking medications associates with heart-rate corrected (QTc) prolongation, such as selective serotonin reuptake inhibitors, quinolones, or macrolides.\n13. Volunteers with acute fascioliasis.\n14. Volunteers who fail to demonstrate adequate understanding of the study after three attempts.","ALL","18 Years","65 Years",{"count":20,"type":21},336,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Randomized clinical trial comparing the efficacy and safety of oxfendazole at 20 mg\u002Fkg per dose in one and two dose regimens with a two-dose regimen of triclabendazole at 10 mg\u002Fkg in an endemic region of the highlands of Peru. Adults with fascioliasis in rural communities will be screened for inclusion and exclusion criteria and a total of 336 subjects (112 per study arm) with chronic Fasciola infection will be enrolled and assigned randomly to the study arms in a 1:1:1 ratio. The primary efficacy (cure and egg reduction) endpoints will be assessed on day 7 and 30 post treatment. The secondary safety endpoint visits will be performed in days 0, 3, 7 and 30 post-treatment and Population Pharmacokinetics (PK) modeling studies will be performed in the first 24 hours after the first dose of oxfendazole.",[27],"Fascioliasis","NOT_YET_RECRUITING","2026-06-01",{"date":31,"type":32},"2026-06-03","ACTUAL",{"date":34,"type":21},"2026-08-15",{"date":36,"type":21},"2029-04-15",{"name":38,"class":39},"Universidad Peruana Cayetano Heredia","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100559544","phase-2-oxfendazole-in-mild-parenchymal-brain-cysticercosis-100559544","NCT06565507","Oxfendazole in Mild Parenchymal Brain Cysticercosis","A Double-blind Multicenter, Randomized Controlled Trial of Single and Multiple Dose Regimens of Oxfendazole for Mild (One or Two Lesions) Parenchymal Brain Cysticercosis, With an Open Comparison Group","Inclusion Criteria:\n\n1. Male or female individuals between 18 and 75 years of age, with suspected viable or degenerating intraparenchymal brain cysticercosis on neuroimaging (CT or MRI) and fulfill the diagnostic criteria for solitary cysticercus granuloma (Rajshekhar and Chandy, 1997)\n2. If female of child-bearing potential and men, willing to use an adequate method of contraception\\*, including implants, injectables, combined oral contraceptives, effective intrauterine devices, sexual abstinence, or vasectomized partner while participating in the study.\n3. Patients with normal laboratory values for hemoglobin, platelet counts, total white blood cells, glucose, creatinine, bilirubin, ALT, and AST.\n4. Availability to grant informed consent.\n\nExclusion Criteria:\n\n1. Multiple lesion sites or more than two adjacent lesions.\n2. Suspected neurotuberculosis (Rajshekhar's criteria) \\[66,67\\]\n3. More than two viable brain cysts.\n4. Large brain cysts (\\> 3cm in diameter)\n5. Subarachnoid neurocysticercosis or intraventricular\n6. Untreated ocular cysticercosis\n7. Previous therapy with ABZ (does not include patients who received single-dose 400 mg ABZ for intestinal parasites), or PZQ in the past twelve months.\n8. Active pulmonary tuberculosis evidenced by a positive chest X-ray and positive sputum smears.\n9. Systemic disease other than NCC that may affect therapy or short-term prognosis, including but not limited to chronic renal failure, hepatic insufficiency, cardiac failure, and steroid-dependent immune diseases.\n10. Patients in unstable condition or with severe intracranial hypertension (ICH). Definition of severe ICH for this study would be the presence of headaches, nausea, and vomiting, and papilledema at fundoscopic examination.\n11. Pregnancy\n12. History of hypersensitivity to ABZ or PZQ\n13. Concurrent treatment with cimetidine, ranitidine, or theophylline.\n14. Chronic alcohol or drug abuse.\n15. Positive to Strongyloides infection\n16. History of reported allergy to contrast substances used in MRI.","75 Years",{"count":49,"type":21},544,[24,51],"PHASE3","The goal of this clinical trial is to compare a single and multiple dose regimens of oxfendazole with the standard treatment in patients with mild (one or two lesions) parenchymal brain cysticercosis. The main question it aims to answer is if OXF will enhance clearance of brain parasites and therefore provide greater cysticidal efficacy, with the potential to provide a single-dose therapy for this type of NCC.\n\nThe study cohort will also allow us to identify early imaging markers that predict lesion resolution, as well as factors associated with residual calcification or focal gliosis after lesion resolution. This study will also provide additional information on the safety of the study interventions.",[54],"Brain Cysticercosis",[56,57],"Cysticercosis","Cysticercosis treatment","2026-04-27",{"date":60,"type":32},"2026-05-01",{"date":62,"type":21},"2026-12-01",{"date":64,"type":21},"2030-12-15",{"name":38,"class":39},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100592136","implementation-of-the-community-health-system-innovation-project-in-low--and-middle--income-countries-100592136","NCT06989502","Implementation of the COmmunity HEalth System InnovatiON Project in Low- and Middle- Income Countries","GH Project: NIHR150261 - Implementation of the COmmunity HEalth System InnovatiON Project, COHESION-I","COHESION-I","Inclusion Criteria for PHC users with diabetes, hypertension, and\u002For NTDs:\n\n* Males or females aged 18 years and over, from the selected sites\n* Having used the health services in the previous three months\n* Diagnosis (or estimated risk) of diabetes mellitus type 2, hypertension, or neurocysticercosis\n* Must be able to listen to radio programs, or other audio material\n\nInclusion Criteria for PHC users without diabetes, hypertension, and\u002For NTDs:\n\n* Males or females aged 18 years and over, from the selected sites\n* Having used the health services in the previous three months\n* Must be able to listen to radio programs, or other audio material\n\nExclusion Criteria for PHC users without diabetes, hypertension, and\u002For NTDs:\n\n\\- Diagnosis (or estimated risk) of diabetes mellitus type 2, hypertension, or neurocysticercosis\n\nThe criteria mentioned above refer solely to the quantitative evaluation. For the other types of evaluation, some different populations will be included (such as healthcare workers, local authorities and other stakeholders).",true,{"count":76,"type":21},2094,[78],"NA","The COHESION-I project will evaluate the effects of the co-creation intervention (2016 to 2019) and the co-design intervention (2023 to 2024) on improving (a) health system responsiveness, and (b) patient satisfaction, at the primary health care level, in Peru, Nepal and Mozambique, in relation to chronic diseases (hypertension, and diabetes mellitus), as well as specific neglected tropical diseases. Each intervention has been tailored to the context and characteristics of each one of the aforementioned low- and middle-income countries.\n\nFor this quasi-experimental study, three arms were established: the co-creation (2016 to 2019) + co-design (2023 to 2024) arm; the co-design only (2023 to 2024) arm; and the control group (no intervention; usual care). The evaluation will be composed of four types of evaluations: quantitative; qualitative; economic; and process evaluation",[81,82,83],"Hypertension","Diabetes Mellitus","Neglected Tropical Diseases",[81,82,83,85,86,87,88],"Chronic Disease","Primary Health Care","Implementation Science","Low and Middle Income Countries","2025-05-16",{"date":91,"type":32},"2025-05-25",{"date":93,"type":21},"2025-05-17",{"date":95,"type":21},"2026-11-30",{"name":38,"class":39},3,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":107,"enrollmentInfo":4,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":116,"locationsCount":4},"100154098","pilot-study-using-a-heat-pack-to-treat-cutaneous-leishmaniasis-100154098","NCT01277796","Pilot Study Using a Heat Pack to Treat Cutaneous Leishmaniasis","Pilot Study of Thermotherapy Treatment for Cutaneous Leishmaniasis in Peru With the HECT-CL Device","HECT","Inclusion Criteria:\n\n* with CL diagnosed by skin smear (WHO method), biopsy, culture, PCR\n* aged 8-80 years old\n* with no more than 3 lesions\n* ulcerative and non-ulcerative ulcers less than 4 cm diameter.\n* allergy, prohibitive side effects to standard chemotherapy, or other contraindication to antimonial treatment (e.g. cardiac arrhythmia)\n* capable of signing an informed consent or having capable guardians (in the case of minors).\n* Children ≥ 8 years of age must give written or verbal informed assent along with written consent of their guardians.\n\nExclusion Criteria:\n\n* lesions less than 2cm from the nose, mouth, ears, or eyes.\n* clinically diagnosed with mucosal involvement.\n* evidence of lymph node involvement on exam.\n* unable or unwilling to commit to the treatment and follow-up plan.\n* prior CL treatment within last 1 month.\n* pregnant or lactating\n* uncontrolled severe systemic illness or immunocompromised state.","8 Years","80 Years","EXPANDED_ACCESS","Current standard therapies with chemotherapy (CT) for Cutaneous Leishmaniasis (CL) are expensive, toxic\u002Fallergenic, frequently ineffective, burdensome, and often unavailable. Thermotherapy is a clinically validated first line alternative for the treatment of Cutaneous Leishmaniasis in South America. However, current heat-delivery modalities are either too costly or lack governmental approval required to be made widely available to endemic areas. The investigators have adapted a reliable, safe, and low-cost heat pack for Cutaneous Leishmaniasis that the investigators have named the HECT-CL device. In this pilot study the investigators will enroll 25 patients who have either failed or are not candidates for pentivalent antimonies. The hypothesis states that the HECT-CL device demonstrates efficacy non-statistically inferior to estimates for current South American Pentavalent Antimonial cure rates (76%) while demonstrating basic safety and tolerability.",[111],"Cutaneous Leishmaniasis","AVAILABLE","2011-01-14",{"date":115,"type":21},"2011-01-17",{"name":38,"class":39},""]